Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan
© 2026 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest
The author has received honoraria for lectures from Olympus, FUJIFILM Medical, Daiichi-Sankyo, Miyarisan Pharmaceutical, AI Medical Service, and Astra Zeneca.
Funding
None.
Acknowledgments
The authors thank Edanz (https://jp.edanz.com/ac) for editing a draft of the manuscript.
ER, endoscopic resection; CRT, chemoradiotherapy; HR, hazard ratio; CI, confidence interval; OS, overall survival; PFS, progression-free survival; high-risk patients, submucosa cancer with lymphovascular invasion; low-risk patients; muscularis mucosa cancer with lymphovascular invasion or submucosa cancer without lymphovascular invasion; NA, not assessed.
Based on ref. 43
SM, submucosa; LVI, lymphovascular invasion; MM, muscularis mucosa; VMX, residual tumor in the vertical margin cannot be assessed.
Adapted from Ishihara, et al. Dig Endosc 2025 Jul 6 [Epub]. https://doi.org/10.1111/den.15082, with permission.27
| Study | Country | Subject | Risk factors of metastasis |
|---|---|---|---|
| Duan et al.28 | China | M, 50; SM, 93 | cancer invasion depth, lesion size, location, differentiation |
| Kadota et al.22 | Japan | SM, 108 | cancer invasion depth, LVI, lesion size |
| Zhou et al.30 | China | M, 160; SM, 338 | cancer invasion depth, LVI, lesion size, differentiation |
| Qi et al.31 | China | SM, 258 | LVI, tumor volume |
| Li et al.32 | China | M, 47; SM, 142 | cancer invasion depth, LVI |
| Xue et al.33 | China | M, 52; SM, 219 | cancer invasion depth, EGFR, VEGF |
| Kim et al.34 | Korea | M, 64; SM, 133 | lesion size, LVI, macroscopic type |
| Shimada et al.29 | Japan | M, 37; SM, 123 | Lymphatic invasion, intramural meta |
| Eguchi et al.12 | Japan | M, 100; SM, 364 | Cancer invasion depth, LVI |
| Esophagectomy (% or % [n/total n]) | CRT (% or % [n/total n]) | HR (95% CI) for CRT | |
|---|---|---|---|
| 5-Year OS | |||
| All patients | 89.1 | 90.0 | 0.89 (0.54–1.45) |
| High-risk patients | 84.5 | 82.6 | 1.41 (0.71–2.83) |
| Low-risk patients | 92.3 | 94.5 | 0.56 (0.27–1.16) |
| 5-Year PFS | |||
| All patients | 83.7 | 86.6 | 1.04 (0.66–1.62) |
| High-risk patients | 79.8 | 81.0 | 1.50 (0.79–2.83) |
| Low-risk patients | 86.6 | 91.0 | 0.66 (0.34–1.28) |
| Metastatic recurrence | |||
| All patients | 9.4 (15/160) | 12.5 (20/160) | NA |
| High-risk patients | 13.4 (9/67) | 17.9 (12/67) | NA |
| Low-risk patients | 6.5 (6/93) | 8.6 (8/93) | NA |
| Retrospective study using esophagectomy and follow-up data | Metastasis rate (% [n/total n patients]) |
|---|---|
| SM1, LVI– | 8.0 (2/25) |
| SM2, LVI– | 9.4 (3/32) |
| MM, LVI+ | 25.7 (9/35) |
| SM1, LVI+ | 32.3 (10/31) |
| SM2, LVI+ | 27.7 (13/47) |
| VMX or 1, LVI– | 20 (3/15) |
| VMX or 1, LVI+ | 35.1 (13/37) |
| Study | Country | Subject | Risk factors of metastasis |
|---|---|---|---|
| Duan et al.28 | China | M, 50; SM, 93 | cancer invasion depth, lesion size, location, differentiation |
| Kadota et al.22 | Japan | SM, 108 | cancer invasion depth, LVI, lesion size |
| Zhou et al.30 | China | M, 160; SM, 338 | cancer invasion depth, LVI, lesion size, differentiation |
| Qi et al.31 | China | SM, 258 | LVI, tumor volume |
| Li et al.32 | China | M, 47; SM, 142 | cancer invasion depth, LVI |
| Xue et al.33 | China | M, 52; SM, 219 | cancer invasion depth, EGFR, VEGF |
| Kim et al.34 | Korea | M, 64; SM, 133 | lesion size, LVI, macroscopic type |
| Shimada et al.29 | Japan | M, 37; SM, 123 | Lymphatic invasion, intramural meta |
| Eguchi et al.12 | Japan | M, 100; SM, 364 | Cancer invasion depth, LVI |
ER, endoscopic resection; CRT, chemoradiotherapy; HR, hazard ratio; CI, confidence interval; OS, overall survival; PFS, progression-free survival; high-risk patients, submucosa cancer with lymphovascular invasion; low-risk patients; muscularis mucosa cancer with lymphovascular invasion or submucosa cancer without lymphovascular invasion; NA, not assessed. Based on ref.
SM, submucosa; LVI, lymphovascular invasion; MM, muscularis mucosa; VMX, residual tumor in the vertical margin cannot be assessed. Adapted from Ishihara, et al. Dig Endosc 2025 Jul 6 [Epub].
M, mucosal cancer; SM, submucosal cancer; LVI, lymphovascular invasion; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor.
